Trial Outcomes & Findings for Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT) (NCT NCT02745119)

Last Updated: 2019-03-06

Results Overview

An AE was defined as any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether considered related to the medicinal product, any new disease or exacerbation of an existing disease, recurrence of an intermittent medical condition, or any deterioration in a laboratory value or other clinical test. Ocular AEs are the events which are localized in the ocular region.

Recruitment status

TERMINATED

Study phase

PHASE3

Target enrollment

994 participants

Primary outcome timeframe

Up to approximately one year

Results posted on

2019-03-06

Participant Flow

994 participants enrolled in study . study terminated early by Sponsor due to lack of efficacy. 842 patients received at least one lampalizumab injection 152 patients enrolled in Study GX30191 did not receive study drug in the extension study and thus were excluded from the safety-evaluable population.

Eligible participants were those who enrolled in Studies GX29176 (NCT02247479) and GX29185 (NCT02247531) and had completed the 96-week treatment period without early treatment discontinuation or study discontinuation.

Participant milestones

Participant milestones
Measure	Lampalizumab Q4W - Treatment-Naive Participants who received sham comparator every 4 weeks in one of the parent studies and completed the Week 96 visit received lampalizumab, 10 milligrams (mg), by intravitreal (ITV) injection, administered every 4 weeks.	Lampalizumab Q4W - Previously Treated Participants who received lampalizumab every 4 weeks in one of the parent studies and completed the Week 96 visit received lampalizumab, 10 mg, by ITV injection, administered every 4 weeks.	Lampalizumab Q6W - Treatment-Naive Participants who received sham comparator every 6 weeks in one of the parent studies and completed the Week 96 visit received lampalizumab, 10 mg, by ITV injection, administered every 6 weeks.	Lampalizumab Q6W - Previously Treated Participants who received lampalizumab every 6 weeks in one of the parent studies and completed the Week 96 visit received lampalizumab, 10 mg, by ITV injection, administered every 6 weeks.
Overall Study STARTED	145	274	146	277
Overall Study COMPLETED	0	0	0	0
Overall Study NOT COMPLETED	145	274	146	277

Reasons for withdrawal

Reasons for withdrawal
Measure	Lampalizumab Q4W - Treatment-Naive Participants who received sham comparator every 4 weeks in one of the parent studies and completed the Week 96 visit received lampalizumab, 10 milligrams (mg), by intravitreal (ITV) injection, administered every 4 weeks.	Lampalizumab Q4W - Previously Treated Participants who received lampalizumab every 4 weeks in one of the parent studies and completed the Week 96 visit received lampalizumab, 10 mg, by ITV injection, administered every 4 weeks.	Lampalizumab Q6W - Treatment-Naive Participants who received sham comparator every 6 weeks in one of the parent studies and completed the Week 96 visit received lampalizumab, 10 mg, by ITV injection, administered every 6 weeks.	Lampalizumab Q6W - Previously Treated Participants who received lampalizumab every 6 weeks in one of the parent studies and completed the Week 96 visit received lampalizumab, 10 mg, by ITV injection, administered every 6 weeks.
Overall Study Adverse Event	1	0	1	3
Overall Study Death	3	3	0	4
Overall Study Lost to Follow-up	0	0	0	1
Overall Study Protocol Deviation	0	0	0	1
Overall Study Withdrawal by Subject	7	15	8	14
Overall Study Study Terminated by Sponsor	134	252	135	251
Overall Study Physician Decision	0	2	2	2
Overall Study Reason Not Specified	0	2	0	1

Baseline Characteristics

Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT)

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Lampalizumab Q4W - Treatment-Naive n=145 Participants Participants who received sham comparator every 4 weeks in one of the parent studies and completed the Week 96 visit received lampalizumab, 10 milligrams (mg), by intravitreal (ITV) injection, administered every 4 weeks.	Lampalizumab Q4W - Previously Treated n=274 Participants Participants who received lampalizumab every 4 weeks in one of the parent studies and completed the Week 96 visit received lampalizumab, 10 mg, by ITV injection, administered every 4 weeks.	Lampalizumab Q6W - Treatment-Naive n=146 Participants Participants who received sham comparator every 6 weeks in one of the parent studies and completed the Week 96 visit received lampalizumab, 10 mg, by ITV injection, administered every 6 weeks.	Lampalizumab Q6W - Previously Treated n=277 Participants Participants who received lampalizumab every 6 weeks in one of the parent studies and completed the Week 96 visit received lampalizumab, 10 mg, by ITV injection, administered every 6 weeks.	Total n=842 Participants Total of all reporting groups
Age, Continuous	79.0 years STANDARD_DEVIATION 8.2 • n=5 Participants	78.7 years STANDARD_DEVIATION 7.8 • n=7 Participants	79.2 years STANDARD_DEVIATION 8.6 • n=5 Participants	80.2 years STANDARD_DEVIATION 7.9 • n=4 Participants	79.3 years STANDARD_DEVIATION 8.0 • n=21 Participants
Sex: Female, Male Female	82 Participants n=5 Participants	167 Participants n=7 Participants	79 Participants n=5 Participants	164 Participants n=4 Participants	492 Participants n=21 Participants
Sex: Female, Male Male	63 Participants n=5 Participants	107 Participants n=7 Participants	67 Participants n=5 Participants	113 Participants n=4 Participants	350 Participants n=21 Participants
Race/Ethnicity, Customized American Indian or Alaska Native	0 Participants n=5 Participants	1 Participants n=7 Participants	1 Participants n=5 Participants	0 Participants n=4 Participants	2 Participants n=21 Participants
Race/Ethnicity, Customized Asian	0 Participants n=5 Participants	0 Participants n=7 Participants	1 Participants n=5 Participants	0 Participants n=4 Participants	1 Participants n=21 Participants
Race/Ethnicity, Customized Black or African American	0 Participants n=5 Participants	1 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	1 Participants n=21 Participants
Race/Ethnicity, Customized White	145 Participants n=5 Participants	269 Participants n=7 Participants	141 Participants n=5 Participants	272 Participants n=4 Participants	827 Participants n=21 Participants
Race/Ethnicity, Customized Multiple	0 Participants n=5 Participants	0 Participants n=7 Participants	2 Participants n=5 Participants	2 Participants n=4 Participants	4 Participants n=21 Participants
Race/Ethnicity, Customized Unknown	3 Participants n=5 Participants	2 Participants n=7 Participants	1 Participants n=5 Participants	1 Participants n=4 Participants	7 Participants n=21 Participants
Race/Ethnicity, Customized Hispanic or Latino	2 Participants n=5 Participants	3 Participants n=7 Participants	4 Participants n=5 Participants	12 Participants n=4 Participants	21 Participants n=21 Participants
Race/Ethnicity, Customized Not Hispanic or Latino	140 Participants n=5 Participants	267 Participants n=7 Participants	140 Participants n=5 Participants	263 Participants n=4 Participants	810 Participants n=21 Participants
Race/Ethnicity, Customized Not Reported	0 Participants n=5 Participants	2 Participants n=7 Participants	1 Participants n=5 Participants	1 Participants n=4 Participants	4 Participants n=21 Participants

PRIMARY outcome

Timeframe: Up to approximately one year

Population: The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.

Outcome measures

Outcome measures
Measure	Lampalizumab Q4W - Treatment-Naive n=145 Participants Participants who received sham comparator every 4 weeks in one of the parent studies and completed the Week 96 visit received lampalizumab, 10 milligrams (mg), by intravitreal (ITV) injection, administered every 4 weeks.	Lampalizumab Q4W - Previously Treated n=274 Participants Participants who received lampalizumab every 4 weeks in one of the parent studies and completed the Week 96 visit received lampalizumab, 10 mg, by ITV injection, administered every 4 weeks.	Lampalizumab Q6W - Treatment-Naive n=146 Participants Participants who received sham comparator every 6 weeks in one of the parent studies and completed the Week 96 visit received lampalizumab, 10 mg, by ITV injection, administered every 6 weeks.	Lampalizumab Q6W - Previously Treated n=277 Participants Participants who received lampalizumab every 6 weeks in one of the parent studies and completed the Week 96 visit received lampalizumab, 10 mg, by ITV injection, administered every 6 weeks.	All Participants n=842 Participants All participants in the study received lampalizumab 10 mg, ITV, Q4W or Q6W.
Percentage of Participants With Ocular Adverse Events (AEs) by Severity Mild	25.5 percentage of participants	26.6 percentage of participants	16.4 percentage of participants	21.7 percentage of participants	23.0 percentage of participants
Percentage of Participants With Ocular Adverse Events (AEs) by Severity Moderate	9.7 percentage of participants	11.3 percentage of participants	8.2 percentage of participants	10.1 percentage of participants	10.1 percentage of participants
Percentage of Participants With Ocular Adverse Events (AEs) by Severity Any severity	37.2 percentage of participants	40.1 percentage of participants	24.7 percentage of participants	33.2 percentage of participants	34.7 percentage of participants
Percentage of Participants With Ocular Adverse Events (AEs) by Severity Severe	2.1 percentage of participants	2.2 percentage of participants	0 percentage of participants	1.4 percentage of participants	1.5 percentage of participants

PRIMARY outcome

Timeframe: Up to approximately one year

Population: The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.

Outcome measures

Outcome measures
Measure	Lampalizumab Q4W - Treatment-Naive n=145 Participants Participants who received sham comparator every 4 weeks in one of the parent studies and completed the Week 96 visit received lampalizumab, 10 milligrams (mg), by intravitreal (ITV) injection, administered every 4 weeks.	Lampalizumab Q4W - Previously Treated n=274 Participants Participants who received lampalizumab every 4 weeks in one of the parent studies and completed the Week 96 visit received lampalizumab, 10 mg, by ITV injection, administered every 4 weeks.	Lampalizumab Q6W - Treatment-Naive n=146 Participants Participants who received sham comparator every 6 weeks in one of the parent studies and completed the Week 96 visit received lampalizumab, 10 mg, by ITV injection, administered every 6 weeks.	Lampalizumab Q6W - Previously Treated n=277 Participants Participants who received lampalizumab every 6 weeks in one of the parent studies and completed the Week 96 visit received lampalizumab, 10 mg, by ITV injection, administered every 6 weeks.	All Participants n=842 Participants All participants in the study received lampalizumab 10 mg, ITV, Q4W or Q6W.
Percentage of Participants With Systemic (Non-Ocular) AEs by Severity Mild	18.6 percentage of participants	20.1 percentage of participants	17.8 percentage of participants	20.9 percentage of participants	19.7 percentage of participants
Percentage of Participants With Systemic (Non-Ocular) AEs by Severity Severe	8.3 percentage of participants	13.5 percentage of participants	5.5 percentage of participants	10.1 percentage of participants	10.1 percentage of participants
Percentage of Participants With Systemic (Non-Ocular) AEs by Severity Any severity	55.2 percentage of participants	54.0 percentage of participants	41.8 percentage of participants	51.3 percentage of participants	51.2 percentage of participants
Percentage of Participants With Systemic (Non-Ocular) AEs by Severity Moderate	28.3 percentage of participants	20.4 percentage of participants	18.5 percentage of participants	20.2 percentage of participants	21.4 percentage of participants

PRIMARY outcome

Timeframe: Week 48

Population: The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study. Data is reported for evaluable participants.

The immunogenicity analysis included participants with at least one predose and one postdose anti-lampalizumab antibodies assessment. Predose was defined as prior to the first dose in the extension study for the prior sham participants, and prior to the first dose in the parent study for the prior lampalizumab participants.

Outcome measures

Outcome measures
Measure	Lampalizumab Q4W - Treatment-Naive n=145 Participants Participants who received sham comparator every 4 weeks in one of the parent studies and completed the Week 96 visit received lampalizumab, 10 milligrams (mg), by intravitreal (ITV) injection, administered every 4 weeks.	Lampalizumab Q4W - Previously Treated n=274 Participants Participants who received lampalizumab every 4 weeks in one of the parent studies and completed the Week 96 visit received lampalizumab, 10 mg, by ITV injection, administered every 4 weeks.	Lampalizumab Q6W - Treatment-Naive n=146 Participants Participants who received sham comparator every 6 weeks in one of the parent studies and completed the Week 96 visit received lampalizumab, 10 mg, by ITV injection, administered every 6 weeks.	Lampalizumab Q6W - Previously Treated n=277 Participants Participants who received lampalizumab every 6 weeks in one of the parent studies and completed the Week 96 visit received lampalizumab, 10 mg, by ITV injection, administered every 6 weeks.	All Participants n=842 Participants All participants in the study received lampalizumab 10 mg, ITV, Q4W or Q6W.
Percentage of Participants With Anti-Lampalizumab Antibodies	0.0 percentage of participants	0.0 percentage of participants	0.0 percentage of participants	0.0 percentage of participants	0.0 percentage of participants

Adverse Events

Lampalizumab Q4W - Treatment-Naive

Serious events: 31 serious events

Other events: 41 other events

Deaths: 3 deaths

Lampalizumab Q4W - Previously Treated

Serious events: 58 serious events

Other events: 63 other events

Deaths: 3 deaths

Lampalizumab Q6W - Treatment-Naive

Serious events: 14 serious events

Other events: 26 other events

Deaths: 0 deaths

Lampalizumab Q6W - Previously Treated

Serious events: 50 serious events

Other events: 56 other events

Deaths: 9 deaths

All Participants

Serious events: 153 serious events

Other events: 186 other events

Deaths: 15 deaths

Serious adverse events

Serious adverse events
Measure	Lampalizumab Q4W - Treatment-Naive n=145 participants at risk Participants who received sham comparator every 4 weeks in one of the parent studies and completed the Week 96 visit received lampalizumab, 10 milligrams (mg), by intravitreal (ITV) injection, administered every 4 weeks.	Lampalizumab Q4W - Previously Treated n=274 participants at risk Participants who received lampalizumab every 4 weeks in one of the parent studies and completed the Week 96 visit received lampalizumab, 10 mg, by ITV injection, administered every 4 weeks.	Lampalizumab Q6W - Treatment-Naive n=146 participants at risk Participants who received sham comparator every 6 weeks in one of the parent studies and completed the Week 96 visit received lampalizumab, 10 mg, by ITV injection, administered every 6 weeks.	Lampalizumab Q6W - Previously Treated n=277 participants at risk Participants who received lampalizumab every 6 weeks in one of the parent studies and completed the Week 96 visit received lampalizumab, 10 mg, by ITV injection, administered every 6 weeks.	All Participants n=842 participants at risk All participants in the study received lampalizumab 10 mg, ITV, Q4W or Q6W.
Cardiac disorders Cardiac failure congestive	0.00% 0/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	1.4% 4/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.48% 4/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Eye disorders Visual acuity reduced	0.69% 1/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	1.5% 4/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.68% 1/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.72% 2/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.95% 8/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Eye disorders Neovascular age-related macular degeneration	0.69% 1/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.36% 1/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.68% 1/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.72% 2/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.59% 5/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Eye disorders Ocular hypertension	0.00% 0/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.73% 2/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.24% 2/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Eye disorders Visual impairment	0.69% 1/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.36% 1/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.24% 2/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Eye disorders Dellen	0.00% 0/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.36% 1/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.12% 1/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Eye disorders Dry age-related macular degeneration	0.69% 1/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.12% 1/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Eye disorders Iritis	0.00% 0/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.36% 1/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.12% 1/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Eye disorders Vitreous haemorrhage	0.69% 1/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.12% 1/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Infections and infestations Endophthalmitis	0.00% 0/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.68% 1/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.36% 1/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.24% 2/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Injury, poisoning and procedural complications Corneal abrasion	0.00% 0/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.36% 1/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.68% 1/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.24% 2/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Investigations Intraocular pressure increased	2.1% 3/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	1.5% 4/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.68% 1/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	1.8% 5/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	1.5% 13/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Blood and lymphatic system disorders Iron deficiency anaemia	0.00% 0/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.36% 1/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.12% 1/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Cardiac disorders Atrial fibrillation	1.4% 2/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	1.1% 3/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.36% 1/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.71% 6/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Cardiac disorders Bradycardia	0.69% 1/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.36% 1/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.24% 2/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Cardiac disorders Myocardial infarction	0.69% 1/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.36% 1/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.24% 2/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Cardiac disorders Acute myocardial infarction	0.69% 1/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.12% 1/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Cardiac disorders Angina pectoris	0.69% 1/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.12% 1/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Cardiac disorders Atrial flutter	0.00% 0/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.36% 1/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.12% 1/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Cardiac disorders Cardiac failure	0.00% 0/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.36% 1/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.12% 1/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Cardiac disorders Diastolic dysfunction	0.00% 0/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.36% 1/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.12% 1/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Cardiac disorders Tachycardia	0.00% 0/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.36% 1/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.12% 1/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Gastrointestinal disorders Abdominal pain	0.00% 0/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.36% 1/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.72% 2/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.36% 3/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Gastrointestinal disorders Ileus	0.00% 0/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.72% 2/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.24% 2/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Gastrointestinal disorders Abdominal incarcerated hernia	0.00% 0/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.36% 1/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.12% 1/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Gastrointestinal disorders Colitis	0.69% 1/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.12% 1/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Gastrointestinal disorders Diverticulum intestinal	0.00% 0/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.36% 1/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.12% 1/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Gastrointestinal disorders Gastrointestinal haemorrhage	0.00% 0/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.36% 1/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.12% 1/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Gastrointestinal disorders Malabsorption	0.69% 1/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.12% 1/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Gastrointestinal disorders Upper gastrointestinal haemorrhage	0.69% 1/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.12% 1/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Gastrointestinal disorders Vomiting	0.00% 0/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.36% 1/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.12% 1/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
General disorders Chest pain	0.69% 1/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.73% 2/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.68% 1/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.36% 1/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.59% 5/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
General disorders Death	0.69% 1/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	1.1% 3/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.48% 4/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
General disorders Oedema peripheral	0.00% 0/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.36% 1/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.12% 1/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
General disorders Sudden cardiac death	0.00% 0/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.36% 1/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.12% 1/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
General disorders Systemic inflammatory response syndrome	0.69% 1/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.12% 1/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Hepatobiliary disorders Cholecystitis	0.00% 0/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.36% 1/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.12% 1/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Hepatobiliary disorders Cholelithiasis	0.00% 0/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.36% 1/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.12% 1/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Infections and infestations Pneumonia	2.1% 3/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.73% 2/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	1.4% 2/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	1.8% 5/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	1.4% 12/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Infections and infestations Influenza	1.4% 2/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.36% 1/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.72% 2/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.59% 5/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Infections and infestations Cellulitis	0.00% 0/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.73% 2/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.36% 1/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.36% 3/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Infections and infestations Sepsis	0.69% 1/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.36% 1/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.24% 2/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Infections and infestations Bacteraemia	0.00% 0/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.36% 1/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.12% 1/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Infections and infestations Bronchitis	0.00% 0/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.36% 1/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.12% 1/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Infections and infestations Central nervous system infection	0.00% 0/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.36% 1/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.12% 1/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Infections and infestations Clostridium difficile colitis	0.69% 1/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.12% 1/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Infections and infestations Device related infection	0.00% 0/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.36% 1/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.12% 1/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Infections and infestations Diverticulitis	0.00% 0/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.36% 1/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.12% 1/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Infections and infestations Enterocolitis bacterial	0.69% 1/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.12% 1/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Infections and infestations Escherichia bacteraemia	0.00% 0/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.36% 1/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.12% 1/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Infections and infestations Osteomyelitis	0.00% 0/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.36% 1/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.12% 1/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Infections and infestations Urinary tract infection	0.69% 1/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.12% 1/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Injury, poisoning and procedural complications Fall	0.00% 0/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	1.5% 4/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.68% 1/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	1.8% 5/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	1.2% 10/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Injury, poisoning and procedural complications Hip fracture	0.00% 0/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.68% 1/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.72% 2/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.36% 3/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Injury, poisoning and procedural complications Pelvic fracture	0.00% 0/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	1.1% 3/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.36% 3/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Injury, poisoning and procedural complications Femoral neck fracture	0.00% 0/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.36% 1/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.36% 1/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.24% 2/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Injury, poisoning and procedural complications Foot fracture	0.00% 0/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.36% 1/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.36% 1/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.24% 2/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Injury, poisoning and procedural complications Radius fracture	0.00% 0/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.36% 1/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.36% 1/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.24% 2/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Injury, poisoning and procedural complications Tendon rupture	0.00% 0/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.72% 2/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.24% 2/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Injury, poisoning and procedural complications Ankle fracture	0.00% 0/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.36% 1/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.12% 1/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Injury, poisoning and procedural complications Femur fracture	0.00% 0/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.36% 1/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.12% 1/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Injury, poisoning and procedural complications Fracture displacement	0.69% 1/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.12% 1/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Injury, poisoning and procedural complications Hand fracture	0.00% 0/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.36% 1/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.12% 1/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Injury, poisoning and procedural complications Laceration	0.00% 0/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.36% 1/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.12% 1/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Injury, poisoning and procedural complications Lumbar vertebral fracture	0.00% 0/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.36% 1/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.12% 1/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Injury, poisoning and procedural complications Spinal fracture	0.00% 0/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.36% 1/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.12% 1/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Injury, poisoning and procedural complications Upper limb fracture	0.00% 0/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.36% 1/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.12% 1/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Investigations Blood lactic acid increased	0.00% 0/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.36% 1/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.12% 1/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Investigations International normalised ratio increased	0.69% 1/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.12% 1/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Metabolism and nutrition disorders Dehydration	0.69% 1/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.68% 1/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.36% 1/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.36% 3/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Metabolism and nutrition disorders Hyponatraemia	0.69% 1/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.36% 1/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.24% 2/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Metabolism and nutrition disorders Gout	0.00% 0/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.36% 1/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.12% 1/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Metabolism and nutrition disorders Hypoalbuminaemia	0.69% 1/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.12% 1/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Metabolism and nutrition disorders Hypoglycaemia	0.00% 0/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.36% 1/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.12% 1/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Metabolism and nutrition disorders Hypokalaemia	0.69% 1/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.12% 1/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Metabolism and nutrition disorders Hypovolaemia	0.69% 1/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.12% 1/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Musculoskeletal and connective tissue disorders Osteoarthritis	0.00% 0/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.36% 1/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.68% 1/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.36% 1/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.36% 3/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Musculoskeletal and connective tissue disorders Arthritis	0.00% 0/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.73% 2/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.24% 2/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Musculoskeletal and connective tissue disorders Back pain	0.00% 0/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.68% 1/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.12% 1/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Musculoskeletal and connective tissue disorders Coccydynia	0.00% 0/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.36% 1/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.12% 1/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Musculoskeletal and connective tissue disorders Intervertebral disc protrusion	0.69% 1/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.12% 1/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Musculoskeletal and connective tissue disorders Joint instability	0.69% 1/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.12% 1/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Musculoskeletal and connective tissue disorders Pain in extremity	0.69% 1/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.12% 1/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Musculoskeletal and connective tissue disorders Rotator cuff syndrome	0.00% 0/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.36% 1/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.12% 1/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Colon cancer	0.00% 0/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.36% 1/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.68% 1/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.24% 2/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Prostate cancer metastatic	0.00% 0/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.36% 1/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.68% 1/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.24% 2/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Adenocarcinoma gastric	0.00% 0/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.36% 1/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.12% 1/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Basal cell carcinoma	0.00% 0/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.36% 1/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.12% 1/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Bladder neoplasm	0.00% 0/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.68% 1/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.12% 1/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Breast cancer	0.00% 0/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.36% 1/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.12% 1/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Myelodysplastic syndrome	0.69% 1/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.12% 1/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Neoplasm malignant	0.00% 0/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.36% 1/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.12% 1/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Pancreatic carcinoma	0.00% 0/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.36% 1/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.12% 1/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Pancreatic carcinoma metastatic	0.69% 1/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.12% 1/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Skin cancer	0.00% 0/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.36% 1/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.12% 1/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Small cell lung cancer metastatic	0.00% 0/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.36% 1/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.12% 1/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Squamous cell carcinoma of the vulva	0.00% 0/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.36% 1/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.12% 1/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Nervous system disorders Cerebrovascular accident	0.00% 0/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.73% 2/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.24% 2/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Nervous system disorders Transient ischaemic attack	0.00% 0/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.73% 2/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.24% 2/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Nervous system disorders Cerebral small vessel ischaemic disease	0.69% 1/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.12% 1/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Nervous system disorders Dementia with lewy bodies	0.00% 0/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.36% 1/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.12% 1/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Nervous system disorders Ischaemic stroke	0.00% 0/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.36% 1/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.12% 1/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Nervous system disorders Syncope	0.00% 0/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.36% 1/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.12% 1/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Nervous system disorders Wernicke's encephalopathy	0.00% 0/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.36% 1/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.12% 1/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Psychiatric disorders Hallucination	0.00% 0/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.68% 1/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.12% 1/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Psychiatric disorders Mental status changes	0.00% 0/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.36% 1/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.12% 1/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Renal and urinary disorders Acute kidney injury	0.00% 0/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.68% 1/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.36% 1/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.24% 2/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Renal and urinary disorders Renal artery stenosis	0.00% 0/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.36% 1/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.12% 1/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Renal and urinary disorders Renal failure	0.00% 0/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.36% 1/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.12% 1/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Reproductive system and breast disorders Cystocele	0.00% 0/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.36% 1/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.12% 1/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Reproductive system and breast disorders Postmenopausal haemorrhage	0.00% 0/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.36% 1/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.12% 1/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Reproductive system and breast disorders Rectocele	0.00% 0/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.36% 1/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.12% 1/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Respiratory, thoracic and mediastinal disorders Acute respiratory failure	0.69% 1/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.72% 2/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.36% 3/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Respiratory, thoracic and mediastinal disorders Pneumonia aspiration	0.69% 1/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.36% 1/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.24% 2/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Respiratory, thoracic and mediastinal disorders Pulmonary embolism	0.00% 0/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.36% 1/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.36% 1/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.24% 2/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Respiratory, thoracic and mediastinal disorders Pulmonary fibrosis	0.00% 0/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.36% 1/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.68% 1/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.24% 2/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Respiratory, thoracic and mediastinal disorders Chronic obstructive pulmonary disease	0.00% 0/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.36% 1/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.12% 1/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Respiratory, thoracic and mediastinal disorders Dyspnoea	0.00% 0/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.36% 1/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.12% 1/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Respiratory, thoracic and mediastinal disorders Epistaxis	0.00% 0/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.36% 1/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.12% 1/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Respiratory, thoracic and mediastinal disorders Hypercapnia	0.00% 0/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.36% 1/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.12% 1/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Respiratory, thoracic and mediastinal disorders Hypoxia	0.00% 0/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.36% 1/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.12% 1/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Respiratory, thoracic and mediastinal disorders Pleurisy	0.00% 0/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.36% 1/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.12% 1/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Respiratory, thoracic and mediastinal disorders Respiratory distress	0.00% 0/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.68% 1/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.12% 1/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Respiratory, thoracic and mediastinal disorders Respiratory failure	0.00% 0/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.36% 1/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.12% 1/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Respiratory, thoracic and mediastinal disorders Sleep apnoea syndrome	0.69% 1/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.12% 1/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Vascular disorders Aortic calcification	0.69% 1/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.12% 1/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Vascular disorders Deep vein thrombosis	0.00% 0/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.36% 1/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.12% 1/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Vascular disorders Hypertension	0.00% 0/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.36% 1/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.12% 1/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Vascular disorders Hypotension	0.00% 0/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.36% 1/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.12% 1/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Vascular disorders Peripheral artery occlusion	0.00% 0/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.68% 1/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.12% 1/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Vascular disorders Temporal arteritis	0.00% 0/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.36% 1/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.12% 1/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Vascular disorders Vasculitis	0.00% 0/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.68% 1/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.12% 1/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Eye disorders Cataract	0.69% 1/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.12% 1/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Injury, poisoning and procedural complications Skull fracture	0.00% 0/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.00% 0/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.36% 1/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	0.12% 1/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.

Other adverse events

Other adverse events
Measure	Lampalizumab Q4W - Treatment-Naive n=145 participants at risk Participants who received sham comparator every 4 weeks in one of the parent studies and completed the Week 96 visit received lampalizumab, 10 milligrams (mg), by intravitreal (ITV) injection, administered every 4 weeks.	Lampalizumab Q4W - Previously Treated n=274 participants at risk Participants who received lampalizumab every 4 weeks in one of the parent studies and completed the Week 96 visit received lampalizumab, 10 mg, by ITV injection, administered every 4 weeks.	Lampalizumab Q6W - Treatment-Naive n=146 participants at risk Participants who received sham comparator every 6 weeks in one of the parent studies and completed the Week 96 visit received lampalizumab, 10 mg, by ITV injection, administered every 6 weeks.	Lampalizumab Q6W - Previously Treated n=277 participants at risk Participants who received lampalizumab every 6 weeks in one of the parent studies and completed the Week 96 visit received lampalizumab, 10 mg, by ITV injection, administered every 6 weeks.	All Participants n=842 participants at risk All participants in the study received lampalizumab 10 mg, ITV, Q4W or Q6W.
Eye disorders Conjunctival haemorrhage	11.7% 17/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	6.2% 17/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	8.2% 12/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	7.2% 20/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	7.8% 66/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Eye disorders Eye pain	5.5% 8/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	2.9% 8/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	3.4% 5/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	4.0% 11/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	3.8% 32/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Infections and infestations Nasopharyngitis	7.6% 11/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	4.4% 12/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	2.1% 3/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	2.2% 6/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	3.8% 32/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Injury, poisoning and procedural complications Fall	7.6% 11/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	4.4% 12/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	3.4% 5/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	5.1% 14/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	5.0% 42/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.
Investigations Intraocular pressure increased	1.4% 2/145 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	8.4% 23/274 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	3.4% 5/146 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	6.1% 17/277 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.	5.6% 47/842 • Up to approximately one year The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.

Additional Information

Medical Communications

Hoffmann-La Roche

Phone: 616878333

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.
Publication restrictions are in place

Restriction type: OTHER